Tapimmune, Inc. (TPIV) Reports Q3 Loss of $0.39

Tapimmune, Inc. (NASDAQ: TPIV) reported Q3 EPS of ($0.39). Revenue for the quarter came in at $0 , versus $0 reported last year.

Recent Corporate and Clinical Developments:

• Appointed Peter Hoang as President and CEO
• Completed enrollment in ongoing Phase 2 dosing study of TPIV200 for treating triple-negative breast cancer (TNBC)
• Began enrolling patients into Phase 2 platinum-sensitive ovarian cancer study under an amended protocol that allows women in their first remission to receive TPIV200 vaccination
• Continued to advance clinical development pipeline in multiple Phase 2 studies in ovarian and breast cancer

Upcoming Anticipated Milestones:

• 2017: Mayo Clinic expected to commence dosing in 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC
• 2017: Publish long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200
• 2017: Complete FDA filings required to initiate studies with TPIV 110 for treating HER2/neu+ breast cancer
• 1H 2018: Report interim immune response data from ongoing Phase 2 TNBC
• 1H 2018: Report interim results from ongoing Phase 2 study of TPIV200 in combination with AstraZeneca\'s durvalumab in patients with platinum-resistant ovarian cancer
• 1H 2018: Mayo Clinic to initiate Phase 1b/2a study of TPIV100 in women with HER2/neu+ ductal carcinoma in situ (DCIS) breast cancer

For earnings history and earnings-related data on Tapimmune, Inc. (TPIV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance